Verastem (VSTM) Finished Goods (2018 - 2026)

Verastem (VSTM) posted quarterly Finished Goods of $67000.0 for Q1 2026, up 86.11% quarter-over-quarter from $36000.0 in Q4 2025.

Analysis

Verastem (VSTM) Finished Goods (2018 - 2026) Analysis & Trends

Verastem's Finished Goods history runs 5 years deep, the most recent figure standing at $67000.0 for Q1 2026.

In Q1 2026, Finished Goods changed N/A year-over-year to $67000.0; the TTM figure through Mar 2026 stood at $67000.0 (changed N/A YoY), while the FY2025 annual figure was $36000.0, changed N/A from the prior year.
Finished Goods for Q1 2026 stood at $67000.0, up from $36000.0 in the prior quarter.
The five-year high for Finished Goods was $67000.0 in Q1 2026, with the low at $14000.0 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Verastem	814.94 Mn	678.59 Mn	36.32 Mn

Historic Data

Download Data